Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA.
Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA.
复制标题
DOI：
10.1158/2159-8290.cd-13-1014
复制
发表时间：
2014-06
期刊：
影响因子：
28.2
通讯作者：
Velculescu VE
中科院分区：
文献类型：
--
作者：
Haber DA;Velculescu VE
通过非侵入性血液取样来研究非血液学癌症是癌症诊断中最令人兴奋和快速发展的领域之一。这主要得益于两方面的重大技术进步，包括完整癌细胞的分离和从血液样本中分析癌细胞来源的DNA，以及分子驱动疗法的越来越多的应用，这依赖于对关键生物标志物的准确和及时的测量。此外，当肿瘤获得耐药性时，这些强有力的癌症治疗方法的显著疗效驱动了对额外遗传变化的选择，这就需要对癌细胞进行重复采样，以根据肿瘤的进化调整治疗。总之，这些先进的非侵入性诊断能力及其在指导精确癌症治疗方面的应用将改变我们选择和监测癌症治疗的方式。循环肿瘤细胞和循环肿瘤DNA分析技术的最新进展为癌症的实时、无创监测奠定了基础，并为癌症的进化、侵袭和转移提供了新的见解。
The ability to study nonhematologic cancers through noninvasive sampling of blood is one of the most exciting and rapidly advancing fields in cancer diagnostics. This has been driven both by major technologic advances, including the isolation of intact cancer cells and the analysis of cancer cell–derived DNA from blood samples, and by the increasing application of molecularly driven therapeutics, which rely on such accurate and timely measurements of critical biomarkers. Moreover, the dramatic efficacy of these potent cancer therapies drives the selection for additional genetic changes as tumors acquire drug resistance, necessitating repeated sampling of cancer cells to adjust therapy in response to tumor evolution. Together, these advanced noninvasive diagnostic capabilities and their applications in guiding precision cancer therapies are poised to change the ways in which we select and monitor cancer treatments. Recent advances in technologies to analyze circulating tumor cells and circulating tumor DNA are setting the stage for real-time, noninvasive monitoring of cancer and providing novel insights into cancer evolution, invasion, and metastasis.